Summary of Significant Accounting Policies (Other Narrative) (Details) - USD ($)		12 Months Ended
	Aug. 02, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Oct. 01, 2019	Sep. 30, 2017
Research and Development Costs
Research and development expenses		$ 136,500,000	$ 139,500,000	$ 135,600,000
Income Taxes
Unrecognized Tax Benefits		3,900,000	9,600,000	6,200,000		$ 4,500,000
Valuation allowances on deferred tax assets		(50,800,000)	(45,000,000.0)
Dispositions
Proceeds on sale of businesses	$ 166,600,000	800,000	166,600,000	1,000,000.0
Gain on sale of perinatal data management system		4,200,000	15,900,000
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Government Grants and Cost Abatement's		3.2
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Deferred Revenue, Additions		300,700,000
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized		(291,300,000)
Other Liabilities and Deferred Revenue, Noncurrent			125,800,000
Capitalized Computer Software, Additions		15,300,000	$ 8,000,000.0	$ 2,400,000
Accounting Standards Update 2018-16 [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Increase (Decrease) in Prepaid Taxes		5,800,000
Accounting Standards Update 2016-02 [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Operating Lease, Right-of-Use Asset					$ 82,500,000
Videomed and Excel
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Deferred Revenue, Additions		$ 2,900,000
Minimum [Member]
Research and Development Costs
Useful life of intangible assets		1 year
Minimum [Member] | Computer Software, Intangible Asset [Member]
Research and Development Costs
Useful life of intangible assets		3 years
Other Noncurrent Liabilities [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Other Liabilities and Deferred Revenue, Noncurrent		$ 138,100,000